New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Heal... (diagnose conditions affecting the blood ...)

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Healing Wounds

Date:3/5/2009

diagnose conditions affecting the blood or bone marrow, such as anemias and leukemia. From this sample, the intention was to grow a particular type of stem cells in the laboratory called mesenchymal stem cells, which are cells that can create other cell types, including those in skin and muscle, and are capable of repopulating damaged skin.

The delivery method used to apply stem cells to the wounds was a fibrin spray system that had not been used in humans prior to the research pioneered by Dr. Falanga and his team. Fibrin is a chemical by-product that occurs naturally in the body and helps clot blood. For each of the three scleroderma patients, up to three spray applications of stem cells were performed.

"For the first time in humans, the investigators used a fibrin spray system -- which takes advantage of the immediate polymerization, or 'gluing,' of stem cells in fibrinogen when mixed with thrombin," said Dr. Falanga. "Both fibrinogen and thrombin are naturally occurring substances in blood which, when mixed to form fibrin, are normally involved in the formation of a clot. In this case, the two substances, highly diluted, were used to deliver the cultured mesenchymal stem cells to the wounds of scleroderma patients in a fine transparent spray."

After delivering the stem cells to the affected finger, the wound was covered and treated with the additional stimulus provided by bioengineered skin -- a bi-layered, substitute skin that consists of living human keratinocytes (cells that make the upper skin layer) and fibroblasts (cells that make collagen) -- derived from neonatal foreskin following a circumcision and preserved for medical research.

From this initial study, Dr. Falanga and his team were very encouraged by their early results. "Our combined approach resulted in dramatic healing of these extremely difficult-to-heal wounds, with new skin growth that blended in nicely with the surrounding sk
'/>"/>

SOURCE American Academy of Dermatology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3
Related medicine technology :

1. New Study Published in the Journal of Drugs in Dermatology Finds DOT Microablative CO2 Laser Optimum for Skin Rejuvenation
2. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
3. Harvard Study Shows Folic Acid, B Vitamins in Animi-3(R) May Prevent Vision Loss
4. Pioneering Diamyd(R) Study to Prevent Childhood Diabetes Approved
5. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
6. TissueGene Announces Regulatory Allowance to Initiate Phase IIa Study of TG-C in South Korea for Osteoarthritis of the Knee
7. Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
8. Laser Burn Injuries in One Eye Can Disrupt Protective Immune Privilege in Both Eyes, Study Finds
9. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
10. New Study Confirms That the Supports Intensity Scale Assessment is Effective in Measuring the Support Needs of People With Intellectual Disability and Making Funding Decisions
11. Childrens Hospital Receives $6.7 Million Grant From Gates Foundation to Study Influenza Vaccine in Pregnant Women in Asia

Post Your Comments:

(Date:12/16/2009)... NEW YORK, December 16 ... the publication of GFT505 (80 mg/day),data ... 50 internationally,recognized expert scientists and clinicians ... the continuing role of generic lipid-modifying,treatments, ... which is commonly observed in patients ...

(Date:12/16/2009)... RealMed has been ranked the #1 Claims ... Top 20 Best in KLAS Awards: Software ... a dynamic revenue cycle management solution providing ... providers and all payers. KLAS ... vendor performance measurement in the software, professional ...

(Date:12/16/2009)... 16 According to Millennium Research Group ... intelligence, health care reforms in China supported rapid ... 2009, and will continue to fuel growth in ... Pacific Markets for Interventional Cardiology Devices 2010 ... government will allow the Chinese drug-eluting stent market ...

Breaking Medicine Technology:International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 2 International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia 3 RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 2 RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service 3 Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2 Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3 Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism 56079 1 Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism 56079 2 Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism 56079 3 Endo Pharmaceuticals Gives Update on Regulatory Status of Testosterone Undecanoate for Men with Hypogonadism 56079 4 Healthcare Debate 3A One Citizens Call for Calm Catches On 56077 1 Healthcare Debate 3A One Citizens Call for Calm Catches On 56077 2 Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 1 Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 2 Connecticut Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 3B 241 Increase Gives State Second Highest Cigarette Tax in the Nation 56075 3

[0] International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia [0] RealMed Ranked as 2009 'Best in KLAS' Claims and Clearinghouse Service [0] Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group

... Romark Laboratories, L.C., a,privately-owned biotechnology company, today announced ... the D.E. Shaw Group., The proceeds from ... its lead compound, nitazoxanide, for the treatment of,hepatitis ... for,the treatment of hepatitis B and C and ...

... to report the,publication of important new research results ... Company,s proprietary compounds. FASgen is a leader in,the ... acid synthase,(FASi), and has conducted extensive research in ... treatment of obesity and fatty,liver disease. The Company ...

Other Medicine Technology:FASgen Announces a New Discovery in Obesity Research 2

Romark Laboratories Raises $18 Million in Institutional Financing FASgen Announces a New Discovery in Obesity Research

(Date:12/17/2009)... provide Baptist with on-going Healthcare Cost/Risk Analysis reports, activity measures ... improvements as it translates toward reduced claim costs and positive ... , ... Jacksonville, FL (PRWEB) ... risk management company specializing in clinical/claims based cost risk analysis ...

(Date:12/16/2009)... BERKELEY, Calif., Dec. 17 If proposed ... new standards in the employer-based insurance system. Approximately ... the age of 65 rely upon employer-based insurance ... House and Senate versions of reform legislation entail ... vast majority of employees work for firms that ...

(Date:12/16/2009)... Benefit of Children with Autism and Other Special Needs, ... Zachary Levi Join Ben Stiller to Ring in the ... -- At its 13th annual Teddy Bear Ball, The ... & CEO Brian Goldner received the ... far-reaching philanthropic leadership and commitment to children,s causes; ...

(Date:12/16/2009)... -- Immucor, Inc. (Nasdaq: BLUD ), a global ... transfusion industry, today announced that Paul D. Mintz, M.D. ... independent director, effective January 1, 2010. ,, Dr. ... medicine for more than 30 years. He is a ... of Virginia School of Medicine. He also serves as ...

(Date:12/16/2009)... ANN ARBOR, Mich., Dec. 16 The most widely ... a finding that raises social justice questions that must ... benefit from stem cell advances, according to a University ... study of its kind, the U-M team analyzed 47 ... commonly used by stem cell researchers. The scientists determined ...

Breaking Medicine News(10 mins):Health News:Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services 2 Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2 Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3 Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 2 Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 3 Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 4 Health News:The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests 5 Health News:Immucor Appoints New Board Director 2 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 2 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 3 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 4 Health News:U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines 5

[0] Baptist Health System Selects HealthScreen Disease Management for Employee Health Management Services [1] How National Health Reform Proposals Would Affect Employer-Based Plans in California [1] The Help Group Honors Brian Goldner, Mary Urquhart and Max Mayer at its Teddy Bear Ball Featuring Ben Stiller and Celebrity Guests [1] Immucor Appoints New Board Director [0] U-M Study Reveals Surprising Lack of Genetic Diversity in the Most Widely Used Human Embryonic Stem Cell Lines

... AIMM) today reported a net loss of $8,000, or break ... September 30, 2007, compared,with a net loss of $36,000, or ... ended September 30, 2006. For the nine months ended,September 30, ... share basic,and diluted, compared with net loss of $517,000, or ...

... Aid Rod,Holder has a suspender-like harness that allows ... The Eliminator Racing Chair is recommended for,athletes with ... in and out,of the chair. (Photo: ... the elements or crave competition, Good Shepherd,Rehabilitation Network,s ...

... tissue, VALLEJO, Calif., Nov. 8 Sutter ... the most advanced and accurate,radiation therapy system available. ... North Bay region customized cancer treatment,resulting in quicker, ... breast, prostate, head, neck and lung cancers. ...

... ROANOKE, Va., Nov. 8 This should be a ... to the next can wear on the body,and dampen the ... can provide you with the comfort, support, and,protection your body ... each other and that requires,some travel for them to be ...

... Nov. 8 Top executives of sports ... Bulletin,Board: NNTN) http://www.naturalnutritioninc.com will be ... Vegas, the world,s largest event for healthy ... 6-8, 2007.,Interactive Nutrition,s professionals constantly travel to,ingredient/packaging ...

... products, SEATTLE, Nov. 8 Cell Therapeutics, Inc. ... has been appointed,the company,s Vice President, Commercial Operations. Fong ... marketing experience. Most recently, Fong,was National Sales Director at ... the launch of Ranexa(R) for chronic angina. CTI,recently agreed ...

Other Medicine News:Health News:AutoImmune Inc. Reports 2007 Third Quarter Financial Results 2 Health News:AutoImmune Inc. Reports 2007 Third Quarter Financial Results 3 Health News:Holiday Gift Giving for Outdoor Enthusiasts With Disabilities and Special Needs 2 Health News:Sutter Solano Cancer Center Offers Oncology Patients Customized Cancer Treatment 2 Health News:Holiday Travel Causing Stress? 2 Health News:Natural Nutrition's Top Executives Attend Supply Side Show West in Las Vegas 2 Health News:Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations 2 Health News:Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations 3

AutoImmune Inc. Reports 2007 Third Quarter Financial Results Holiday Gift Giving for Outdoor Enthusiasts With Disabilities and Special Needs Sutter Solano Cancer Center Offers Oncology Patients Customized Cancer Treatment Holiday Travel Causing Stress?Natural Nutrition's Top Executives Attend Supply Side Show West in Las Vegas Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations

VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...

The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...

Medicine Products:

VascoScrew P 6/60 S VascoScrew E 8/60 S VascoScrew E 6/60 S VascoScrew E 5/60 PU S

New Study Using Combination of Bioengineered Skin and Stem Cells Shows Promise in Treatment of Non-Heal...(diagnose conditions affecting the blood ...),Health